5 Ways AstraZeneca plc Could Make You Rich

Some investors gave up on AstraZeneca plc (LON: AZN) but history has proved them wrong, says Harvey Jones.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

drugs

AstraZeneca (LSE: AZN) (NYSE: AZN.US) appears to be finally turning a corner. Here are five ways it could ultimately make you rich.

1) The surprise factor

Investing in AstraZeneca has been a labour of love in recent years, dividends notwithstanding. An arid drugs pipeline, patent expiries, falling operating profits and European pricing pressures made this a painful business to invest in. Last time I looked at this stock, in October, it traded at 3162p. Now you have to pay 3851p. That sharp 22% gain took me by surprise. And there may be more pleasant surprises to come.

2) By growing faster than expected

Earlier this month, chief executive officer Pascal Soriot cheered markets with this upbeat statement: “Following the acquisition of Bristol-Myers Squibb’s interests in the companies’ diabetes alliance… AstraZeneca continues to believe a return to growth should come earlier than analyst consensus currently forecasts.” He also said the company has made good progress in its three core therapeutic areas of oncology, cardiovascular/metabolic disease, and respiratory, inflammation and autoimmune diseases. The firm’s late-stage pipeline now has 11 Phase-III programmes, almost double last year’s number, and 27 Phase-II programmes. It is great to hear some optimism at last. More please.

3) Because it is nicely priced

Last week, the European Commission granted marketing authorisation for Xigduo, AstraZeneca and Bristol-Myers Squibb‘s treatment for type 2 diabetes. I expect its replenished drugs pipeline to gush out some more good news, lifting the share price. If you invest now, you can buy into this more promising outlook at the modest price of 10 times earnings. That compares nicely to rival GlaxoSmithKline, which trades at a pricier 14.2 times earnings.

4) Demographics are on its side

The Western world is getting older. We’re also getting fatter, and emerging markets are filling out as well. You may see that as bad news. Investors in AstraZeneca may see it in a rather different light. It is targeting new treatments at illnesses of age and affluence, such as heart disease, cancer and diabetes. This makes its decision to buy Bristol-Myers Squibb out of its share in the diabetes business a forward-looking move. Soriot is banking on around 550 million people having diabetes by 2030. That’s a hefty target market.

5) Slowly but surely

AstraZeneca isn’t going to make you rich quick. Earnings per share fell a crunching 23% in 2013, and are expected to continue falling for the next two years, albeit at the slowing pace of 8% in 2015 and 2% in 2015. When Soriot talked of a “faster than expected” return to growth, he meant that 2017 revenues will be broadly in line with 2013 revenues. Investors will have to be patient, but while you wait, you can pocket its 4.4% annual yield, only marginally below Glaxo’s 4.62%. With this stock, it is the dividend that will make you rich in the end.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

> Harvey owns shares in GlaxoSmithKline. The Motley Fool has recommended shares in GlaxoSmithKline.

More on Investing Articles

Illustration of flames over a black background
Investing Articles

2 red-hot UK growth stocks to consider buying in April

These two growth stocks are performing well, but can they continue to deliver for investors through 2024 and beyond?

Read more »

Charticle

Is JD Sports Fashion one of the FTSE 100’s best value stocks? Here’s what the charts say!

The JD Sports Fashion share price remains a wild ride during the first quarter. Could it be one of the…

Read more »

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »